BMP4 Signaling Is Able to Induce an Epithelial-Mesenchymal Transition-Like Phenotype in Barrett's Esophagus and Esophageal Adenocarcinoma through Induction of SNAIL2.

Autor: Christine Kestens, Peter D Siersema, G Johan A Offerhaus, Jantine W P M van Baal

Publikováno v: PLoS ONE, Vol 11, Iss 5, p e0155754 (2016)

BACKGROUND:Bone morphogenetic protein 4 (BMP4) signaling is involved in the development of Barrett's esophagus (BE), a precursor of esophageal adenocarcinoma (EAC). In various cancers, BMP4 has been found to induce epithelial-mesenchymal transition (

Externí odkaz: https://doaj.org/article/c278e2abb18e407b877467420d987b45

Incidence of Progression of Persistent Nondysplastic Barrett's Esophagus to Malignancy

Autor: Christine Kestens, Yonne Peters, Iris D. Nagtegaal, Rachel S. van der Post, Judith Honing, Wiebe R. Pestman, Peter D. Siersema, Wietske Kievit

Publikováno v: Clinical Gastroenterology and Hepatology, 17, 5, pp. 869-877.e5
Clinical Gastroenterology and Hepatology, 17, 869-877.e5

Contains fulltext : 203172.pdf (Author’s version postprint ) (Open Access) BACKGROUND & AIMS: The risk of esophageal adenocarcinoma (EAC) in patients with non-dysplastic Barrett's esophagus (NDBE) is low, so there is debate over the role of ongoing

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05f70b9e4043f7675a7ac4ecdad52c82
https://pubmed.ncbi.nlm.nih.gov/30267865

Adalimumab and Infliximab Are Equally Effective for Crohn's Disease in Patients Not Previously Treated With Anti-Tumor Necrosis Factor-alpha Agents

Autor: Cyriel Y. Ponsioen, Charlotte L. J. Mulder, Dutch Initiative on Crohn, Herma H. Fidder, Gerard Dijkstra, Martijn G.H. van Oijen, Dirk J. de Jong, Christine Kestens, Ad A. van Bodegraven, Bas A. C. van Tuyl, Peter D. Siersema, Colitis, Bas Oldenburg

Publikováno v: Clinical Gastroenterology and Hepatology, 11(7), 826-831. W.B. Saunders Ltd
Clinical Gastroenterology and Hepatology, 11(7), 826-831. ELSEVIER SCIENCE INC
Clinical gastroenterology and hepatology, 11(7), 826-831. W.B. Saunders Ltd
Kestens, C, van Oijen, M G H, Mulder, C L J, van Bodegraven, A A, Dijkstra, G, de Jong, D, Ponsioen, C, van Tuyl, B A C, Siersema, P D, Fidder, H H & Oldenburg, B 2013, ' Adalimumab and Infliximab Are Equally Effective for Crohn's Disease in Patients Not Previously Treated With Anti-Tumor Necrosis Factor-alpha Agents ', Clinical Gastroenterology and Hepatology, vol. 11, no. 7, pp. 826-831 . https://doi.org/10.1016/j.cgh.2013.01.012

BACKGROUND & AIMS: Infliximab (IFX) and adalimumab (ADA) are thought to have equal efficacy for the treatment of Crohn's disease (CD), although no direct comparison has been performed. We compared the effectiveness and safety of IFX and ADA in carefu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ee5a81b07ff12feef87d3d77cf751de
https://doi.org/10.1016/j.cgh.2013.01.012

Profiling of circulating microRNAs in patients with Barrett's esophagus and esophageal adenocarcinoma

Autor: Joost Paulus Hubertus Drenth, Jantine W. P. M. van Baal, Wilbert H.M. Peters, Jeanine M.L. Roodhart, Christine Kestens, Peter D. Siersema, Fiebo Jan Willem Ten Kate, Pauline Bus

Publikováno v: Journal of Gastroenterology, 51, 6, pp. 560-70
Journal of Gastroenterology, 51, 560-70
Journal of Gastroenterology

Background Circulating microRNAs (miRNAs) have been suggested as novel markers for various diseases. The goal of this pilot study was to identify circulating miRNAs differentially expressed comparing Barrett’s esophagus (BE), esophageal adenocarcin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7431117cae5feb47878e26a675b81b2a
https://hdl.handle.net/2066/171269

Treatment of Barrett's esophagus with a novel focal cryoablation device: a safety and feasibility study

Autor: Christine L. Greene, Frank P. Vleggaar, Julian A. Abrams, Jacques J. Bergman, Blair A. Jobe, Peter D. Siersema, Bas L. Weusten, Charles J. Lightdale, Hilary Cosby, Hannah T. Künzli, Elizabeth Tejeda-Ramirez, Christine Kestens, Steven R. DeMeester, Marcia I. Canto, Dirk SchöLvinck, J. H. Peters

Publikováno v: Endoscopy, 47, 12, pp. 1106-12
Endoscopy, 47(12), 1106. Georg Thieme Verlag
Endoscopy, 47, 1106-12
Endoscopy, 47(12), 1106-1112. Georg Thieme Verlag

Item does not contain fulltext BACKGROUND AND AIMS: Currently, eradication of Barrett's epithelium is preferably achieved using radiofrequency ablation (RFA) or spray cryoablation (SCA). However, both modalities suffer from drawbacks such as the need

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f10922f4c134689997e1892d4963abd
https://hdl.handle.net/2066/152889